JP2020517260A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517260A5
JP2020517260A5 JP2019556928A JP2019556928A JP2020517260A5 JP 2020517260 A5 JP2020517260 A5 JP 2020517260A5 JP 2019556928 A JP2019556928 A JP 2019556928A JP 2019556928 A JP2019556928 A JP 2019556928A JP 2020517260 A5 JP2020517260 A5 JP 2020517260A5
Authority
JP
Japan
Prior art keywords
replaced
seq
modified
asn
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517260A (ja
JP7183180B2 (ja
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Application filed filed Critical
Publication of JP2020517260A publication Critical patent/JP2020517260A/ja
Publication of JP2020517260A5 publication Critical patent/JP2020517260A5/ja
Application granted granted Critical
Publication of JP7183180B2 publication Critical patent/JP7183180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556928A 2017-04-21 2018-04-20 C5結合性を欠失したコバーシンバリアント Active JP7183180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
PCT/EP2018/060240 WO2018193121A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding

Publications (3)

Publication Number Publication Date
JP2020517260A JP2020517260A (ja) 2020-06-18
JP2020517260A5 true JP2020517260A5 (enExample) 2021-05-27
JP7183180B2 JP7183180B2 (ja) 2022-12-05

Family

ID=58795719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556928A Active JP7183180B2 (ja) 2017-04-21 2018-04-20 C5結合性を欠失したコバーシンバリアント

Country Status (12)

Country Link
US (2) US11214602B2 (enExample)
EP (1) EP3612207B1 (enExample)
JP (1) JP7183180B2 (enExample)
KR (1) KR102630702B1 (enExample)
CN (1) CN110799207B (enExample)
AU (1) AU2018253961B2 (enExample)
CA (1) CA3060336A1 (enExample)
ES (1) ES2980279T3 (enExample)
GB (1) GB201706406D0 (enExample)
IL (1) IL269856B2 (enExample)
PL (1) PL3612207T3 (enExample)
WO (1) WO2018193121A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7153669B2 (ja) * 2017-04-21 2022-10-14 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 瘢痕性眼炎症障害の治療のためのコバーシン
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
WO2020053206A1 (en) * 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077709A1 (en) * 2000-03-21 2003-04-24 Masazumi Kamohara Novel leukotriene B4 receptor
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
ATE427356T1 (de) 2003-06-02 2009-04-15 Varleigh Ltd Komplementinhibitoren aus zecken
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
JP7153669B2 (ja) * 2017-04-21 2022-10-14 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 瘢痕性眼炎症障害の治療のためのコバーシン
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment

Similar Documents

Publication Publication Date Title
JP2020517260A5 (enExample)
JP2025063029A5 (enExample)
JP2018171063A5 (enExample)
JP2020500015A5 (enExample)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
KR20020026558A (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
RU2018100181A (ru) Модифицированный белок интерлейкина-7 и способы его применения
JP2012520059A5 (enExample)
JPH04281790A (ja) Dnaおよびその用途
JPWO2020072821A5 (enExample)
JP2014506450A5 (enExample)
JP2015523373A (ja) eIF4Eを標的化するための細胞浸透性ペプチド
US11174298B2 (en) Preparation and use of ginsentides and ginsentide-like peptides
JP7677901B2 (ja) グルカゴン様ペプチド-1(glp-1)受容体アゴニストとその類似体の製造プロセス
TW200844230A (en) Signaling peptides
JP2005511038A5 (enExample)
JPWO2020027010A5 (enExample)
JPWO2021191447A5 (enExample)
CN102816213A (zh) 使用固相和液相组合技术制备普兰林肽的方法
WO2016058547A1 (zh) 高活性的肿瘤抑制剂及其制法和应用
JP2020127419A5 (enExample)
JP2019518713A5 (enExample)
JP2015510770A (ja) 組換えペプチドの産生方法
JPWO2021229076A5 (enExample)
AU2022276988B2 (en) Antiviral composition comprising a nucleolin-binding peptide